Drug Formulation Design and Pharmacokinetics for the Treatment of Skin Diseases

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biopharmaceutics".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 1363

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain
2. Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain
Interests: nanotechnology; inflammation diseases; drug delivery systems; nanoemulsions; polymeric and lipidic systems; oral and topical dosage forms
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are delighted to invite you to contribute to a Special Issue of Pharmaceutics focused on “Drug Formulation Design and Pharmacokinetics for the Treatment of Skin Diseases”. This Special Issue aims to highlight the latest research, innovative methodologies, and clinical advancements in the field of dermatological drug delivery and pharmacokinetics. The development of effective treatments for skin diseases requires a comprehensive understanding of drug formulation design and pharmacokinetics. This Special Issue explores innovative approaches to dermatological application, focusing on the formulation of topical agents such as creams, emugels, gels, and transdermal patches. We seek to compile a diverse collection of high-quality manuscripts that investigate the intricacies of topical and transdermal drug delivery systems, novel formulation strategies, and the pharmacokinetic profiles of dermatological treatments. We believe your expertise and contributions would be invaluable to this Special Issue.

We look forward to receiving your contributions.

Dr. Marcelle Silva-Abreu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pharmacokinetic studies of topical and transdermal therapies
  • advanced techniques for assessing drug penetration and distribution
  • optimization of therapeutic efficacy and safety profiles
  • dermatological drug delivery
  • topical formulations
  • skin pharmacokinetics
  • drug penetration
  • transdermal patches
  • creams and gels

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

25 pages, 5837 KiB  
Article
Emulgel Containing Metronidazole and Clindamycin for the Treatment of Rosacea
by Guillermo De Grau-Bassal, Ana Cristina Calpena-Campmany, Marcelle Silva-Abreu, Joaquim Suñer-Carbó, Mireia Mallandrich-Miret, Sergio Martínez-Ruiz, Cecilia Cordero, Alfonso Del Pozo and Núria Bozal-de Febrer
Pharmaceutics 2025, 17(2), 168; https://doi.org/10.3390/pharmaceutics17020168 - 27 Jan 2025
Viewed by 1190
Abstract
Rosacea is a common skin condition with quite a relevance. It currently affects at least 10% of the European population at some point after the age of 30. It is a chronic disorder that mainly affects the skin on the face and is [...] Read more.
Rosacea is a common skin condition with quite a relevance. It currently affects at least 10% of the European population at some point after the age of 30. It is a chronic disorder that mainly affects the skin on the face and is characterized by outbreaks and remissions. Under normal circumstances, the skin face presents a wide range of commensal organisms, such as Staphylococcus epidermidis or Demodex folliculorum, but dysbiosis of the skin flora plays a relevant role in inflammatory processes and the development of the disease. Metronidazole (MD) is one of the main treatments indicated to reduce redness on the cheeks, nose, chin, or forehead and also to treat flushing, erythema, pimples, and other symptoms due in part to its anti-inflammatory action. On the other hand, clindamycin (CM) is another antibiotic used for rosacea, especially for its action against anaerobic and Gram-positive bacteria. Background/Objectives: This study aimed to develop an emulgel formulation that includes MD and CM, using excipients with non-comedogenic and non-irritating properties. Methods: The formulation was characterised physiochemically, rheological measurements were made, and short-term stability studies were carried out. In vitro release, permeation studies, toxicity an in vitro inflammation model were evaluated in a HaCaT cell model. To determine the interaction between the antibiotics, the minimum inhibitory concentration was determined separately and together using the broth microdilution method. To determine the formulation’s antimicrobial activity, an agar diffusion method was used. Results: The MD-CM-gel droplet size was measured by laser diffraction and the diameter obtained was less than 2.68 ± 0.18 µm in 50% of the particles. Suitable results was observed for the short-term stability. Release and permeation data revealed sustained drug release and adequate permeation through human skin. Non-toxicity was detected and the MD showed an anti-inflammatory effect with non-interference of CM. Also, there is no antagonism between the two antibiotics and the MD-CM-gel shows better results when compared to the formulations with the antibiotics separately and to commercial formulations. Conclusions: It is suggested that, following detailed preclinical and clinical studies, MD-CM-gel could be considered as an alternative for treating rosacea. Full article
Show Figures

Figure 1

Back to TopTop